Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis

Xiao Mei Zhang¹ | Peng Fei Li² | Jia Ning Hou² | Li Nong Ji³

¹Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing, China
²Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
³Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, China

Correspondence
Li Nong Ji, Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizimen Nan Da Jie, Xicheng District, Beijing 100044, China.
Email: jiln@bjmu.edu.cn
Jia Ning Hou, MD, Clinical Research Physician, Diabetes Therapeutic Area, Eli Lilly and Company, Lilly Suzhou Pharmaceutical Co. Ltd, 19F, Tower 1 HKRI, Taikoo Hui, No.288, Shi Men No.1 Rd, Shanghai 200041, China.
Email: hou_jia_ning@lilly.com

Funding Information
Eli Lilly and Company

Abstract
Aim: The primary objective of this study was to compare blood glucose (BG) excursions between East Asian and Caucasian patients with type 2 diabetes mellitus (T2DM) who were injection-naive, had inadequate glycemic control with oral antihyperglycemic medications, and who required initiation with injectable therapy.

Methods: This retrospective pooled analysis included individual patient data from completed clinical trials (Insulin lispro injection/dulaglutide development programs, first patient visit ≥1997). All included patients were ≥18 years, were East Asian or Caucasian, and had data for self-monitored BG at baseline. The primary outcome, BG excursion at baseline (least-squares mean, standard error), was compared between patient groups using an analysis of covariance with race as the fixed effect. Independent covariates included baseline body weight, baseline HbA1c, age, and duration of T2DM.

Results: Caucasian (n = 6779) and East Asian (n = 1638) patients from 21 trials were included. BG excursions were significantly higher for East Asian than Caucasian patients at breakfast (4.03 [0.075] vs 2.59 [0.045] mmol/L), lunch (3.37 [0.080] vs 1.43 [0.049] mmol/L), and dinner (3.16 [0.080] vs 1.74 [0.047] mmol/L) (P < 0.001 adjusted analyses). Similar findings were observed for the unadjusted analyses. At each time point, postprandial BG was significantly higher for East Asian than Caucasian patients (with adjusted and unadjusted analyses).

Conclusion: These findings suggest that BG excursion and postprandial BG are higher among East Asian patients with T2DM than Caucasian patients. In addition, these findings may help clinicians select appropriate treatments for East Asian patients with T2DM who require injection therapy.

KEYWORDS
blood glucose excursion, diabetes mellitus, type 2, East Asian
1 | INTRODUCTION

High glycemic variability is common among patients with type 2 diabetes mellitus (T2DM) and is a key contributor to complications associated with inadequate glycemic control. The assessment of postprandial blood glucose (BG) for management of hyperglycemia in patients with T2DM is well recognized, and guidelines now recommend targeting both pre- and postprandial BG to maintain effective glycemic control. However, ethnic differences in the glycemic response and pathophysiology of T2DM may have implications for how T2DM is managed among different populations and for treatment outcomes.

The prevalence of T2DM in Asian populations has increased rapidly in recent years and is associated with high levels of morbidity and mortality. This increase is partly due to changes in lifestyles and diet, and is associated with high levels of morbidity and mortality.

The primary objective of this study was to compare BG excursions between East Asian and Caucasian patients with T2DM, who were injection-naïve, had inadequate glycemic control with OAMs, and who required initiation with injectable therapy. To address this objective, we conducted a retrospective pooled analysis of individual patient data from clinical trials including East Asian and/or Caucasian patients from two Eli Lilly sponsored programs. In addition, we conducted a systematic review of the peer-reviewed literature with published summary data to identify studies reporting baseline BG or BG excursion data for patients who met the inclusion criteria.

2 | MATERIALS AND METHODS

2.1 | Pooled analysis

2.1.1 | Eligibility criteria

In this retrospective post hoc analysis, individual patient data were pooled from completed clinical trials from the Eli Lilly insulin lispro injection (Humalog®) or dulaglutide (Trulicity®) development program. All randomized and nonrandomized clinical trials were eligible for inclusion if they met the following criteria: first patient visit was on or after 1997; enrolled male or female adult (≥18 years) patients with T2DM who were injection-naïve (or had completed a sufficient washout period per individual study requirements); had inadequate glycemic control with OAMs, and required initiation with injectable therapy; and had baseline data for self-monitored blood glucose (SMBG). As only baseline data were included in the analyses, there were no restrictions on study interventions or treatment duration.

2.1.2 | Baseline and analysis variables

The analyses included subpopulations of East Asian and Caucasian patients identified by race/ethnicity as reported in the case report forms. Patients were classified as East Asian if the reported race/ethnicity was East Asian or Asian, and where the patient was located in China, Japan, the Republic of Korea, Hong Kong, or Taiwan. Patients were classified as Caucasian if the reported race/ethnicity was White.

Data extracted from patient-level records included baseline data for age (years), gender, body weight (kg), body mass index (kg/m²), duration of diabetes (years), glycated haemoglobin (HbA1c, %), and baseline BG, and BG excursion based on finger stick SMBG (mmol/L) measurements. If BG excursions were not reported, these were derived from preprandial and postprandial BG measurements.

The primary outcome was BG excursion defined as the difference between preprandial and postprandial BG at breakfast. Secondary outcomes included BG excursion at lunch and dinner, and the daily average BG excursion.

2.1.3 | Statistical analysis

The full analysis set included all eligible randomized patients or all eligible enrolled patients from nonrandomized studies. Mean BG excursion at baseline was compared between East Asian and Caucasian patients using an analysis of covariance. The model included race as the fixed effect and baseline body weight, baseline HbA1c, age, and duration of T2DM as covariates. There was no imputation for missing BG measurements. Data were reported as mean (standard deviation) or least-squares mean (standard error of the mean). Statistical analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC, USA).

2.2 | Systematic review

The methodology for the systematic review is reported in the Supplementary Appendix.

3 | RESULTS

3.1 | Pooled analysis of clinical trials

3.1.1 | Study selection and patient population

Of the 37 clinical trials identified, 21 met the eligibility criteria (Table 1). A total of 6779 Caucasian patients and 1638 East Asian patients from the 21 trials met the criteria for inclusion and their data were pooled for the analyses. As all clinical trials were part of two Eli Lilly clinical development programs, the trials had similar procedures and eligibility criteria. All procedures for the clinical trials were
| Eli Lilly Identifier CT.gov Number | Key Inclusion Criteria at Enrollment | Previous treatment | Analysis Groups (N) Caucasian = 6779 East Asian = 1638 | Patient Characteristics at Baseline (Before Treatment with Study Drug), Mean (SD) | Duration (yr) |
|-----------------------------------|-------------------------------------|-------------------|-----------------------------------------------------|--------------------------------------------------------------------------|--------------|
| H9X-GEBDQ NCT014668181           | 7.0-11.0%                           | Stable dose (≥8 wk) of SU, BG, TZD, α-Gl, or glinide monotherapy for ≥3 mo | EA: 394                                                             | EA: 57.4 (10.96) EA: 71.4 (13.26) EA: 8.5 (1.11) EA: 7.7 (6.29) |              |
| H9X-GEBDY NCT01584232            | 7.0-10.0%                           | Stable dose (≥8 wk) SU or BG | EA: 361                                                             | EA: 56.8 (10.92) EA: 71.0 (13.71) EA: 8.0 (0.85) EA: 8.8 (6.41) |              |
| H9X-MGBCF NCT00734474            | 7.0-9.5% or >8.0-9.5% (diet & exercise) | Diet and exercise, met, OAM, or met + OAM | C: 613 EA: 178                                                      | C: 56.2 (9.46) EA: 52.1 (10.31) C: 93.5 (16.05) EA: 8.1 (1.12) C: 7.1 (5.13) EA: 6.9 (5.09) |              |
| H9X-MGBCJ NCT00630825            | >7.0-10.5%                           | Any combination of 2 of: SU, BG, TZD, DPP-IV inhibitors | C: 151                                                             | C: 59.9 (10.83) C: 98.9 (17.23) C: 8.1 (1.06) C: 8.7 (6.93) C: 8.7 (5.93) |              |
| H9X-MGGBDA NCT01064687           | 1 OAM: 7.0-11.0% 2/3 OAM: 7.0-10.0% | ≤3 OAMs | C: 728                                                             | C: 56.7 (9.65) C: 99.0 (18.82) C: 8.1 (1.37) C: 8.7 (5.40) C: 8.7 (5.40) |              |
| H9X-MGGBDB NCT01075282           | 1 OAM: 7.0-11.0% 2/3 OAM: 7.0-10.0% | ≤3 OAMs | C: 571 EA: 43                                                      | C: 58.5 (9.08) EA: 53.9 (8.66) C: 91.4 (17.77) EA: 8.6 (1.22) C: 9.5 (6.08) EA: 9.3 (6.12) |              |
| H9X-MGGBDE NCT01624259           | 7.0-10.0%                           | Diet and exercise, stable dose (≥3 mo) met (≥1500 mg/day) | C: 515                                                             | C: 57.3 (9.35) C: 94.8 (18.73) C: 8.0 (0.78) C: 7.2 (5.48) C: 7.2 (5.48) |              |
| H9X-MGGBDG NCT01769378           | 7.0-9.5%                           | Stable dose SU (≥50% max dose) for ≥3 mo | C: 250                                                             | C: 58.4 (9.80) C: 86.6 (17.06) C: 8.4 (0.71) C: 7.6 (4.94) C: 7.6 (4.94) |              |
| H9X-MGGBDR NCT01149421           | 7.0-9.5%                           | ≥1 OAM for ≥1 mo | C: 608                                                             | C: 57.0 (10.30) C: 92.9 (19.75) C: 7.9 (0.75) C: 8.5 (5.93) C: 8.5 (5.93) |              |
| F3Z-RIOPH NCT00548808            | 7.0-11.0%                           | OAMs without insulin injection for ≥3 mo | C: 144 EA: 103                                                      | C: 61.0 (8.84) EA: 56.2 (8.25) C: 82.0 (16.44) EA: 8.7 (1.00) C: 11.7 (6.34) EA: 9.8 (4.69) |              |
| F3Z-RIOPQ NCT01773473            | 7.0-11.0%                           | SU, BG, TZD, α-Gl, glinide, or DPP-IV inhibitor monotherapy or combination | C: 29 EA: 374                                                      | C: 54.0 (8.08) EA: 56.7 (9.98) C: 79.8 (11.50) EA: 8.5 (1.09) C: 10.6 (6.90) EA: 9.4 (6.20) |              |
| F3Z-RIOPQ NCT00664534            | 7.0-11.0%                           | Met and ≥1 other OAM (SU or TZD) without insulin for ≥3 mo | C: 331                                                             | C: 55.0 (8.64) C: 84.0 (14.74) C: 9.1 (1.35) C: NR C: 9.1 (1.35) |              |
| F3Z-JE-IOPU NCT00971997           | 7.5-11.0%                           | OAMs (≥3 mo); without insulin for <6 mo | EA: 135                                                             | EA: 60.3 (10.21) EA: 66.6 (14.05) EA: 8.3 (0.80) EA: 11.4 (7.11) |              |
| F3Z-MIOHLb HbA1c 1.2 X ULN        |                                     | OAM (>6 mo) and SU (max dose) and met (500- | C: 92                                                             | C: 56.7 (8.25) C: 82.9 (14.90) C: 9.4 (1.45) C: 10.0 (7.46) C: NR |              |

(Continues)
conducted in accordance with the ethical standards at each site and the relevant Declaration of Helsinki at the time the studies were conducted. Informed consent was obtained from all trial participants. All patients had T2DM, were injection-naive, and had inadequate glycemic control with OAMs at enrollment according to the study inclusion criteria. For most studies, the inclusion criteria required

### TABLE 1 (Continued)

| Eli Lilly Identifier | Key Inclusion Criteria at Enrolment | Analysis Groups (N) | Patient Characteristics at Baseline (Before Treatment with Study Drug), Mean (SD) |
|----------------------|-------------------------------------|---------------------|--------------------------------------------------------------------------------|
| CT.gov Number        |                                     | Caucasian = 6779    | East Asian = 1638                                                              |
| F3Z-MC-IOMAb          | HbA1c 1.2 X ULN                      | OAM (>6 mo) and     | C: 145                                                                         |
|                      |                                     | SU (max dose) for   | C: 67.9 (4.88)                                                                  |
|                      |                                     | ≥1 mo               | C: 78.0 (12.25)                                                                |
|                      |                                     |                     | C: 9.9a (1.40)                                                                 |
|                      |                                     |                     | C: 11.9 (7.57)                                                                 |
| F3Z-MC-IOMYb         | HbA1c 125% X ULN within 4 weeks of   | Single OAM (met or   | C: 531                                                                         |
|                      | study entry                         | second generation   | C: 59.0 (8.83)                                                                  |
|                      |                                     | SU ≥3 mo) with the  | C: 83.6 (15.12)                                                                |
|                      |                                     | last ≥30 days at    | C: 9.1a (1.44)                                                                 |
|                      |                                     | max dose            | C: 7.6 (5.48)                                                                   |
| F3Z-MC-IONDb         | None                                | OAMs without insulin | C: 78                           |
|                      |                                     | (30 days)           | C: 56.2 (9.73)                                                                 |
|                      |                                     |                     | C: 94.6 (18.35)                                                                |
|                      |                                     |                     | C: 8.7a (1.19)                                                                 |
|                      |                                     |                     | C: 8.8 (6.74)                                                                   |
| F3Z-MC-IOXb          | 7.5-12.0%                           | OAM without insulin | C: 293                                                                         |
|                      |                                     | and ≥2 of: met      | C: 61.6 (9.59)                                                                  |
|                      |                                     | 1500 mg/day, SU 1/2 | EA: 56.1 (9.10)                                                                |
|                      |                                     | max dose, TZD 30     | EA: 66.5 (10.42)                                                               |
|                      |                                     | mg/day pioglitazone | EA: 8.8 (0.87)                                                                 |
|                      |                                     | or 4 mg/day rosiglitazone |                       |
|                      |                                     |                     | EA: 12.8 (10.05)                                                               |
| F3Z-US-IOMNb         | ≥8%                                 | OAM and 1700 mg/day | C: 336                                                                         |
|                      |                                     | met for ≥3 mo       | C: 55.2 (10.03)                                                                |
|                      |                                     |                     | C: 97.4a (19.54)                                                               |
|                      |                                     |                     | C: 9.4a (1.48)                                                                 |
|                      |                                     |                     | C: 9.0a (6.06)                                                                 |
| F3Z-US-IONWb         | Jacober et al. Diab Metab Obes 2006;8:448-455  | ≥2 OAMs of different classes in combination for ≥2 mo | C: 45                            |
|                      |                                     |                     | C: 56.2 (9.59)                                                                  |
|                      |                                     |                     | C: 98.4 (18.39)                                                                |
|                      |                                     |                     | C: 9.3a (1.28)                                                                 |
|                      |                                     |                     | C: 8.9 (5.02)                                                                   |
| F3Z-US-IQOVb         |                                     | ≥2 OAMs for ≥3 mo   | C: 1319                                                                         |
|                      |                                     |                     | C: 58.8 (9.45)                                                                  |
|                      |                                     |                     | C: 93.5 (19.88)                                                                |
|                      |                                     |                     | C: 8.9a (1.17)                                                                 |
|                      |                                     |                     | C: 9.8 (6.06)                                                                   |

Abbreviations: α-Gl, alpha-glucosidase inhibitor; BG, biguanide; C, Caucasian; CT.gov, ClinicalTrials.gov; DPP-IV, dipeptidyl peptidase IV; EA, East Asian; HbA1c, glycated haemoglobin; max, maximum; met, metformin; mo, month; NR, not reported; OAM, oral antihyperglycemic medication; SD, standard deviation; SU, sulfonylurea medication; TZD, thiazolidinedione; ULN, upper limit of normal; US, United States; yr, year; wk, week.

aBaseline data are not available for all patients.
bClinical trial identifier not available as the trial was conducted prior to requirements for clinical trial registration.

cOnducted in accordance with the ethical standards at each site and the relevant Declaration of Helsinki at the time the studies were conducted. Informed consent was obtained from all trial participants.

### TABLE 2 Baseline characteristics of patients included in the pooled analysis

| Variablea          | Caucasian Patients (N = 6779) | East Asian Patients (N = 1638) | P Valueb |
|--------------------|------------------------------|-------------------------------|----------|
| Mean age, yr       | 57.9 (9.64)                  | 56.6 (10.49)                  | <0.001   |
| Male, n (%)        | 3687 (54.4)                  | 1024 (62.5)                   | <0.001   |
| Body weight, kg    | 91.6 (18.69)                 | 70.1 (12.79)                  | <0.001   |
| BMI, kg/m²         | 32.2 (5.33)                  | 26.0 (3.63)                   | <0.001   |
| Duration of T2DM, yr| 8.9 (6.05)                  | 8.9 (6.44)                    | 0.885    |
| HbA1c, %           | 8.6 (1.26)                   | 8.4 (1.04)                    | <0.001   |

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus; yr, year.

aAll data are mean (standard deviation) unless otherwise noted.
bFisher exact test for categorical measures, ANOVA model (response = race) for continuous measures.
patients to have HbA1c > 7% at baseline (Table 1). Patients had been diagnosed with T2DM for an average of 8.9 years and had mean HbA1c levels > 7% at baseline (Table 2). However, there were significant differences between the East Asian and Caucasian groups. Compared with the Caucasian group, there was a significantly higher proportion of men in the East Asian group, and patients were significantly younger, with significantly lower body weight, body mass index, and HbA1c levels (Table 2).

3.1.2 | Blood glucose
BG excursions were highest after breakfast in both populations when adjusted for baseline body weight, baseline HbA1c, age, and duration of T2DM, and were significantly higher for East Asian patients than for Caucasian patients (Figure 1, Table 3). In addition, BG excursions were significantly higher for East Asian patients than Caucasian patients at lunch, and dinner, and for the daily average (Figure 1). Similar findings were observed for the unadjusted analyses (Table 3).

BG profiles were significantly different between East Asian and Caucasian patients (Figure 2, Table 3). In the unadjusted analysis, preprandial BG was significantly lower and postprandial BG was significantly higher for East Asian patients than for Caucasian patients at all time points (Figure 2A). The differences in preprandial BG at lunch, dinner, and for the daily preprandial average between East Asian and Caucasian patients were not significant when the analyses were adjusted for baseline body weight, baseline HbA1c, age, and duration of T2DM. However, differences between East Asian and Caucasian patients in all postprandial BG levels remained significant after adjustment for these factors (Figure 2B, Table 3).

3.2 | Systematic review of the literature
Five publications met the eligibility criteria for the systematic review; four studies reported findings in Caucasian populations\(^1\)-17 and one

![Figure 1](image-url)  
**FIGURE 1** Pooled analysis of blood glucose excursion for East Asian and Caucasian injection-naive patients with inadequate glycemic control after oral antihyperglycemic medication. Data are reported as the adjusted least-squares mean difference between postprandial and preprandial blood glucose at each time point. Error bars denote standard error of the mean. * Blood glucose excursions between East Asians and Caucasians were significantly different at each time point ($P < 0.001$, adjusted ANCOVA)

### TABLE 3
Pooled analysis of blood glucose profiles and excursion for East Asian and Caucasian injection-naive patients with inadequate glycemic control after oral antihyperglycemic medication

| Time Point | Unadjusted BG\(^a\), mmol/L | Adjusted BG\(^b\), mmol/L | Unadjusted BG\(^a\), mmol/L | Adjusted BG\(^b\), mmol/L | Unadjusted BG Excursion\(^a\), mmol/L | Adjusted BG Excursion\(^b\), mmol/L |
|------------|---------------------------|--------------------------|---------------------------|--------------------------|----------------------------------|----------------------------------|
|            | N | Mean (SD) | LS mean (SE) | N | Mean (SD) | LS mean (SE) | N | Mean (SD) | LS mean (SE) | N | Mean (SD) | LS mean (SE) |
| Morning    |    |           |               |    |           |               |    |           |               |    |           |               |
| Caucasian  | 3791 | 9.92 (2.806) | 9.76 (0.035) | 3733 | 12.49 (3.689) | 12.32 (0.051) | 3728 | 2.60 (2.495) | 2.59 (0.045) |
| East Asian | 1430 | 9.20 (2.228) | 9.61 (0.060) | 1432 | 13.22 (3.390) | 13.63 (0.085) | 1430 | 4.02 (2.757) | 4.03 (0.075) |
| P value\(^c\) |    | <0.001 | 0.048 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Midday     |    |           |               |    |           |               |    |           |               |    |           |               |
| Caucasian  | 3524 | 9.95 (3.435) | 9.82 (0.047) | 3490 | 11.36 (3.480) | 11.23 (0.051) | 3473 | 1.44 (2.449) | 1.43 (0.049) |
| East Asian | 1426 | 9.48 (3.059) | 9.82 (0.078) | 1425 | 12.97 (3.392) | 13.19 (0.082) | 1425 | 3.48 (3.006) | 3.37 (0.080) |
| P value\(^c\) |    | <0.001 | 0.960 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Evening    |    |           |               |    |           |               |    |           |               |    |           |               |
| Caucasian  | 3766 | 10.02 (3.345) | 9.88 (0.046) | 3742 | 11.77 (3.501) | 11.60 (0.049) | 3729 | 1.78 (2.408) | 1.74 (0.047) |
| East Asian | 1426 | 9.53 (3.150) | 9.85 (0.078) | 1419 | 12.65 (3.493) | 12.97 (0.083) | 1417 | 3.14 (3.112) | 3.16 (0.080) |
| P value\(^c\) |    | <0.001 | 0.767 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Daily      |    |           |               |    |           |               |    |           |               |    |           |               |
| Caucasian  | 3747 | 9.98 (2.877) | 9.82 (0.034) | 3699 | 11.90 (3.220) | 11.74 (0.040) | 3684 | 1.96 (1.524) | 1.95 (0.028) |
| East Asian | 1427 | 9.41 (2.431) | 9.80 (0.058) | 1425 | 12.95 (2.923) | 13.28 (0.068) | 1424 | 3.55 (1.791) | 3.51 (0.048) |
| P value\(^c\) |    | <0.001 | 0.727 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

Abbreviations: BG, blood glucose; HbA1c, glycated haemoglobin; LS least-squares; SD, standard deviation; SE, standard error of the mean.

\(^a\)ANCOVA with race as a fixed effect.

\(^b\)Adjusted for baseline body weight, age, duration of type 2 diabetes mellitus, and baseline HbA1c.

\(^c\)Differences between East Asian and Caucasian groups.
Overall, this study supports preprandial and postprandial blood glucose and adjusted postprandial blood glucose were significantly different between Caucasians and East Asians at preprandial and postprandial blood glucose at each time point. Error bars are not visible as they are within the symbols for each data point. Unadjusted preprandial and postprandial blood glucose and adjusted postprandial blood glucose were significantly different between Caucasians and East Asians for each time point. Error bars are not visible as they are within the symbols for each data point. Unadjusted preprandial and postprandial blood glucose and adjusted postprandial blood glucose were significantly different between Caucasians and East Asians at all time points ($P < 0.001$, ANCOVA); adjusted prebreakfast blood glucose was significantly higher in Caucasians than in East Asians ($P = 0.048$).

FIGURE 2  Pooled analysis of blood glucose profiles for East Asian and Caucasian injection-naive patients with inadequate glycemic control after oral antihyperglycemic medication. A, Unadjusted mean preprandial and postprandial blood glucose at each time point. B, Adjusted least-squares mean preprandial and postprandial blood glucose at each time point. Error bars are not visible as they are within the symbols for each data point. Unadjusted preprandial and postprandial blood glucose and adjusted postprandial blood glucose were significantly different between Caucasians and East Asians at all time points ($P < 0.001$, ANCOVA); adjusted prebreakfast blood glucose was significantly higher in Caucasians than in East Asians ($P = 0.048$).

study$^{12}$ reported findings separately for Caucasian and/or East Asian populations. There was a tendency for higher BG excursions at breakfast, lunch, and dinner in East Asian patients than in Caucasian patients (Supplementary Table S1). However, there was a high level of variability in BG excursions within each study and between each of the study populations. Meta analyses were not conducted because there were insufficient data to compare East Asian with Caucasian populations. Details of the search results are reported in the Supplementary Appendix.

4 | DISCUSSION

This study is the first to compare BG profiles of injection-naive East Asian patients and Caucasian patients with T2DM and an inadequate glycemic response to OAMs using a pooled analysis of patient-level data. Overall, this large, retrospective pooled analysis of 8417 injection-naive patients with T2DM demonstrated higher postprandial BG levels and greater BG excursions in East Asian patients compared with Caucasian patients following breakfast, lunch, and dinner. These findings were evident even after adjusting for patient body weight, baseline HbA1c, age, and duration of T2DM. Evidence from the peer-reviewed literature was limited and, of the five studies retrieved, only one study reported BG profiles of East Asian patients.$^{12}$ However, findings from the literature were generally supportive of the pooled analysis. Overall, this study supports evidence from studies conducted in Taiwan and Japan$^{10,11}$ and a post hoc subgroup analysis of patients from China and the Republic of Korea$^{12}$ that postprandial BG is an important treatment target among East Asian patients with T2DM.

Given the complex pathophysiology of T2DM, the reasons for the difference in BG profiles between East Asian and Caucasian populations are likely to be multifactorial and related to both lifestyle and diet, and to ethnic differences in insulin resistance and the capacity to secrete insulin.$^{7}$ Asian populations have higher glycemia in response to the same carbohydrate load$^{8}$ and higher daily intake of carbohydrate compared with Caucasian populations.$^{9,10}$ Greater insulin resistance is observed in Asian populations, possibly because of higher levels of visceral fat per body weight or waist circumference compared with Caucasian populations.$^{5,18}$ Also the capacity to secrete insulin appears to have a more predominant role in T2DM among Asian populations compared with Caucasians, particularly in those who are of lean body weight.$^{7,19-21}$ In this study, East Asian patients were of lower body weight than their Caucasian counterparts. However, the differences in BG profiles remained statistically significant after adjustment for body weight (as well as baseline HbA1c, age, and duration of T2DM) in the analyses.

Differences in BG profiles among patients with T2DM of different races and ethnicities may have implications for how T2DM is managed and for treatment outcomes. Patients in Asia have earlier onset and longer duration of T2DM and are at a higher risk of microvascular complications, particularly renal disease, compared with Caucasians.$^{5,22,23}$ Analysis of BG profiles among Caucasian patients with T2DM who were insulin-naive has shown that the contribution of postprandial BG to excess hyperglycemia decreases relative to fasting BG in poorly controlled patients.$^{24}$ In contrast, several studies have shown that targeting postprandial BG is as important as targeting preprandial BG for management of hyperglycemia among East Asian patients who are poorly controlled on OAMs, before receiving injectable treatment$^{10}$ and among those on insulin.$^{10,11}$ Analysis of Asian patients with T2DM who were insulin-naive has shown that the contribution of postprandial BG to 4-hour excess hyperglycemia after meals and 24-hour excess hyperglycemia is similar to the contribution of preprandial BG/fasting BG, respectively, in poorly controlled patients (HbA1c $>7\%$).$^{10}$ In addition, findings from a retrospective post hoc analysis of patients with T2DM of different ethnicities showed that Asian patients had a greater need for, and higher doses of, mealtime insulin than non-Asian patients on basal insulin glargine plus prandial insulin lispro.$^{12}$ Together with the current study, these findings suggest that postprandial BG is an important treatment target in East Asian populations and suggests that East Asian patients may have a greater and earlier need of therapies. Indeed, assessment of treatment patterns from noninterventional studies has shown that use of premixed insulins in Asian populations is widespread, with approximately one-third of Japanese patients commencing insulin with a premixed insulin$^{25}$ and approximately two-thirds of Chinese patients on OAMs using a premixed insulin.$^{26}$
The main strength of this study was the large number of patients available for analysis from multiple clinical studies with similar eligibility criteria and procedures. Significant differences in BG profiles and excursions between the East Asian and Caucasian groups were observed in the unadjusted analyses and after analyses were adjusted to take into account differences in baseline characteristics between the groups. However, interpretation of the findings should take into account the retrospective nature of the analyses and that the included studies were not designed to compare BG profiles of patients from different ethnicities. As this was a post-hoc pooled analysis, our intention was to show whether there were differences in BG profiles between the two ethnic groups. We did not match the baseline characteristics and demographics between East Asian and Caucasian patients. Therefore, it was impossible to explore the reasons for the differences observed in this study. Although the included clinical studies were very similar in design, the interpretation of the findings should take into account that data were pooled data from two clinical trial programs that were conducted at different times, and that included patients with various OAM treatment regimens, and patients from different Caucasian populations. The systematic review of the literature confirmed the rationale for conducting a pooled analysis and showed that there is limited information in the peer-reviewed literature on postprandial BG before commencing injectable treatment. Moreover, there was a high degree of variability in the data available from the peer-reviewed literature; only one study included data on BG excursion at baseline and only one study reported on BG excursions in East Asian patients.

In conclusion, findings from this retrospective pooled analysis of individual patient data showed significantly higher postprandial BG excursions in East Asian patients with T2DM who were injection-naive and had inadequate glycemic control with OAMs compared with Caucasian patients. These findings have clinical implications for the effect of ethnicity on the BG profiles in patients with T2DM and suggest that there should be greater emphasis on the control of BG excursions in East Asian patients. In addition, these findings may help clinicians select appropriate treatments for East Asian patients with T2DM who require injection therapy.

CONFLICT OF INTEREST

J.N.H. is an employee of Eli Lilly and Company. P.F.L. was an employee of Eli Lilly and Company at the time of manuscript preparation. L.N.J. has received consulting and lecture fees from Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi, Roche and Boehringer Ingelheim, and has received research grants from Roche and Sanofi. X.M.Z. has no conflicts of interest to declare.

FUNDING SUPPORT

This study was sponsored by Eli Lilly and Company, manufacturer/licensee of several injectable insulins and GLP-1 agonists. Medical writing assistance was provided by Serina Stretton, PhD, CMPP and Rebecca Lew, PhD, CMPP of ProScribe—Envision Pharma Group, and was funded by Eli Lilly and Company. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP3).

ROLE OF THE SPONSOR

Eli Lilly and Company was involved in the study design, data collection, data analysis, and preparation of the manuscript.

ROLE OF CONTRIBUTORS

All authors participated in the drafting, critical revision, and approval of the final version of the manuscript. All authors participated in the interpretation of the study results. X.M.Z., J.N.H., and L.N.J were involved in the conception of the study and the study design, and P.F.L. was involved in data collection and conducted the statistical analyses.

ORCID

Jia Ning Hou  http://orcid.org/0000-0002-7210-0110
Li Nong Ji  http://orcid.org/0000-0002-3262-2168

REFERENCES

1. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006;49(5):846-854.
2. Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425-436.
3. International Diabetes Foundation. 2011 Guideline for Management of PostMeal Glucose in Diabetes. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/82:management-of-postmeal-glucose.html. Accessed Sep 21, 2017.
4. Dickinson S, Colagioni S, Faramus E, Petocz P, Brand-Miller JC. Post-prandial hyperglycaemia and insulin sensitivity differ among lean young adults of different ethnicities. J Nutr. 2002;132(9):2574-2579.
5. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-2140.
6. Ma RC, Chan JC. Type 2 diabetes in east Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64-91.
7. Hulman A, Simmons RK, Brunner EJ, et al. Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. Diabetologia. 2017;60(7):1252-1260.
8. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375(9712):408-418.
9. Zuniga YL, Rebello SA, Oi PL, et al. Rice and noodle consumption is associated with insulin resistance and hyperglycaemia in an Asian population. Br J Nutr. 2014;111(06):1118-1128.
10. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27(1):79-84.
11. Shimizu H, Uehara Y, Okada S, et al. Contribution of fasting and post-prandial hyperglycaemia to hemoglobin A1C in insulin-treated Japanese diabetic patients. Endocr J. 2008;55(4):753-756.
12. Ji L, Min KW, Oliveira J, Lew T, Duan R. Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study. Diabetes Metab Syndr Obes. 2016;9:243-249.
13. Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. *Diabet Med*. 2012;29(9):e263-e272.

14. Lalic NM, Micic D, Antic S, et al. Effect of biphasic insulin aspart on glucose and lipid control in patients with type 2 diabetes mellitus. *Expert Opin Pharmacother*. 2007;8(17):2895-2901.

15. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. *Diabetes Obes Metab*. 2013;15(7):642-649.

16. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. *Diabetes Obes Metab*. 2006;114(09):527-532.

17. Franek E, Haluzik M, Canecki Varzic S, et al. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with type 2 diabetes. *Diabet Med*. 2016;33(4):497-505.

18. Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. *Int J Obes (Lond)*. 2006;30(7):1163-1165.

19. Staimez LR, Weber MB, Ranjani H, et al. Evidence of reduced beta-cell function in Asian Indians with mild dysglycemia. *Diabetes Care*. 2013;36(9):2772-2778.

20. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. *Metabolism*. 2004;53(7):831-835.

21. Chan WB, Tong PC, Chow CC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese type 2 diabetic patients. *Diabet Med*. 2004;21(4):349-353.

22. Li J, Dong Y, Wu T, Tong N. Differences between western and Asian type 2 diabetes patients in the incidence of vascular complications and mortality: a systematic review of randomized controlled trials on lowering blood glucose. *J Diabetes*. 2016;8(6):824-833.

23. Lanting LC, Joung IM, Mackenbach JP, et al. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. *Diabetes Care*. 2005;28(9):2280-2288.

24. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. *Diabetes Care*. 2003;26(3):881-885.

25. Freemantle N, Balkau B, Danchin N, et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. *Diabetes Obes Metab*. 2012;14(10):901-909.

26. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. *BMC Public Health*. 2013;13(1):602.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

---

**How to cite this article:** Zhang XM, Li PF, Hou JN, Ji LN. Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis. *Diabetes Metab Res Rev*. 2018;34:e3062. [https://doi.org/10.1002/dmrr.3062](https://doi.org/10.1002/dmrr.3062)